NetworkNewsAudio – CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial
Related Press Release CNS Pharmaceuticals (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently announced the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer. These first European clinical trial sites in France and Spain are now open and actively enrolling patients. To view the original press release, visit https://www.nnw.fm/nedBq About CNS Pharmaceuticals Inc.…







